Navigation Links
Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
Date:9/10/2012

SUNNYVALE, Calif. and SEATTLE, Sept. 10, 2012 /PRNewswire/ -- Sorbent Therapeutics, Inc. a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today presented positive data from its randomized, double-blind Phase 2a clinical study of CLP1001.  In the study of 111 heart failure patients with chronic kidney disease, CLP1001 demonstrated improvement in heart failure symptoms as compared to placebo.   

Data from the Phase 2a study were presented by Barry M. Massie, M.D., Professor, University of California, San Francisco, President of the Heart Failure Society of America and member of Sorbent's Medical Advisory Board, during the Late-Breaking News Symposium at the Heart Failure Society of America 16th Annual Scientific Meeting in Seattle, Washington.  

"The results of this clinical study suggest that CLP1001 may provide important benefits in addressing the signs and symptoms of heart failure," said Dr. Massie.  "Specifically, the reduction of dyspnea and improved physical functionality among patients dosed with CLP1001 are associated with a better quality of life in heart failure patients already on standard guideline recommended medications."

"Heart failure symptoms are generally debilitating – in spite of currently available therapies.  The positive findings from our Phase 2a clinical trial indicate that CLP1001 may improve patient outcomes," said Howard C. Dittrich, M.D., F.A.C.C., Sorbent's Chief Medical Officer.  "We look forward to working closely with the clinical community on additional clinical studies where we plan to measure the effects of CLP10001 on the physical functionality and overall quality of life of heart failure patients when administered in combination with standard medications for heart failure."

About the Phase 2a Study and Reported Clinical Results

The double-blind, randomized, parallel, placebo-controlled study examined the effe
'/>"/>

SOURCE Sorbent Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
2. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
3. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
4. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
5. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
6. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Global Markets for Animal Therapeutics and Diagnostics
10. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... -- Investor-Edge has initiated coverage on the following ... and Company (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... and Novartis AG (NYSE: NVS ). Free research ... . On Friday, December 12, 2014, the NASDAQ ... Average lost 1.79%, to finish the day at 17,280.83, and ...
(Date:12/15/2014)... , December 15, 2014 ... development company, is pleased to announce the grant of ... relating to its GPCR-focused drug discovery platform. ... strengthens the global patent estate covering Heptares, technologies and ... suite of patents recently granted by the US Patent ...
(Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
(Date:12/15/2014)... 2014 SIMpalm, a leading mobile ... for iPhone for its client, which allows users to ... company, specialized in finding the right wine. At ... uses combined sensory, chemistry and wine information. All this ... “wine fingerprint.” Those wines that are close counterparts to ...
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. 12, ... the millions of American women who have migraine: The debilitating ... is no association between migraine and breast cancer risk," said ... Harvard Medical School. "There is no positive association, so there ... effect either." About 18 percent of American women and ...
(Date:12/15/2014)... SIMSBURY, CT (PRWEB) December 15, 2014 ... in the prestigious Women World Awards in the category ... of a gold award for her weekly career blog ... and practical advice to help professionals elevate their talent ... Her blog, named after her book Networking Ahead ...
(Date:12/15/2014)... CA (PRWEB) December 15, 2014 At ... the organizations AutismOne and Focus Autism ... enlighten attendees with research on the effects of toxins ... testing and intervention information. , Luminaries such as ... researchers from abroad with esteemed, credentialed colleagues of the ...
(Date:12/15/2014)... La Jolla, Calif. (PRWEB) December 15, 2014 ... Roasters made the Coffee Review “Top 30 Coffees of 2014.” ... number two, and their Guji Zone Ethiopia at number 10. ... list twice. , Coffee Review’s selection is ranked on ... The Sumatra Ulos Batak scored 96 out of 100, and ...
Breaking Medicine News(10 mins):Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... clinic, injecting an anesthetic at certain points can reduce the ... is being presented today at the annual meeting of the ... Diego, had found that about 16% of patients encounter a ... was explained that the biopsies are commonly performed on men ...
... a new type of insulin that is inhaled rather ... respiratory infection or are exposed to passive smoke.// ... for treatment of diabetes. It uses an inhaler developed ... for healthcare providers," Professor Philippe Camus of the University ...
... the Queen’s Balmoral Castle in Scotland kills cancer cells and ... the University of Maribor in Slovenia said that they placed ... them to those placed in normal lab water. ,They ... cancer cells 62.5 percent more quickly than normal water. In ...
... nurses will be given ?5,000 to retrain ... Scotland. Health minister Andy Kerr said that ... million over two years on this plan.// ... nurses who are trained outside Europe and ...
... that "any disorder in human faculties" increases dependence on ... Abdul Kalam Wednesday urged researchers to "direct their efforts ... affected by autism".// ,Equality can be generated ... skills and engaging the minds of affected children in ...
... Fatigue is so common among Americans that it almost ... says that although the underlying cause of persistent fatigue ... fatigue is imaginary.// ,According to Boosting Your Energy, ... emotionally. Still, most people—even those being treated for fatigue-producing ...
Cached Medicine News:Health News:Autistic Children Need Sense of Equality: A.P.J. Abdul Kalam 2Health News:Boosting Energy Naturally 2
... only test designed specifically for detecting ... pH. It includes a convenient pH ... range which is important in monitoring ... can now spend less time testing ...
... is recognized by medical professionals as the ... its accuracy, convenience and affordability. CLOtest was ... with Robin Warren, M.D. was the first ... and gastric ulcers. Today, CLOtest has become ...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... Rapid Test Strip and Device are rapid ... antibodies to Helicobacter pylori (H. pylori) in ... in the diagnosis of H. pylori infection ... older. They are intended for health professionals ...
Medicine Products: